A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories


June 29, 2007
Designer Enzyme to Fight HIV Shows Promise
Scientists in Germany have constructed a custom enzyme that reverses the process by which HIV inserts its genetic material into a CD4 cell's DNA, suggesting that treatment with similar enzymes could potentially rid infected cells of the virus.
June 26, 2007
Treatment Improves Survival Among IDUs
(AIDSmeds.com) Survival among HIV-infected intravenous drug users (IDUs) has improved dramatically since the introduction of combination antiretroviral therapy, with survival rates similar to HIV-negative IDUs.
June 25, 2007
Dietary Supplement Rule Announced, Questioned
(AIDSmeds.com) The FDA has announced plans to ensure the quality of dietary supplements. But does the new rule go far enough?
June 22, 2007
Drug-Resistant HIV in Semen Stirs Concerns
(AIDSmeds.com) Drug-resistant HIV can remain detectable in the male genital tract for an extended period of time, and potentially prolong the risk to sexual partners, according to a study published in the August 1 issue of the Journal of Infectious Disease.
June 21, 2007
Hep B and HIV Baraclude Users Beware
(AIDSmeds.com) Treating hepatitis B patients with the drug Baraclude® (entecavir) can cause those who are also infected with HIV to become resistant to two vital HIV drugs, according to a new report in the New England Journal of Medicine.
Panacos' Bevirimat Back on Track
(AIDSmeds.com) Panacos Pharmaceuticals reports that it is back on track with the development of its maturation inhibitor bevirimat (PA-457), after hitting a dosing snag reported in December 2006.
June 20, 2007
Maraviroc: Approvable, but not yet Approved
(AIDSmeds.com) Pfizer has learned from the FDA that its entry inhibitor maraviroc is "approvable," but not yet approved.
June 19, 2007
Reyataz May Cause Kidney Stones
(AIDSmeds.com) The FDA has received 30 reports of kidney stones among HIV-positive patients being treated with Reyataz, prompting the company to update the drug's package insert.
Death Rates Higher Among Rural Positive Patients - But Why?
(AIDSmeds.com) A new study confirms that HIV-positive people residing in rural areas of the U.S. are more likely to die than those who live in urban areas. Unfortunately, few explanations for this disparity were apparent to the researchers.
June 15, 2007
Several Factors Raise Women's Bone Loss Risk
(AIDSmeds.com) Decreased bone mineral density (BMD) is both highly prevalent and severe among underweight women with HIV and is associated with other factors like menstrual irregularities, reduced testosterone levels, lower lean body mass, and white race.
June 14, 2007
Racially and Gender Diverse Aptivus Study Underway
(AIDSmeds.com) Researchers are now enrolling patients into its SPRING clinical trial, one of the largest racially and gender diverse international studies of highly treatment-experienced HIV-positive patients.
June 12, 2007
LDL Drops with Sustiva to Viramune Switch
(AIDSmeds.com) HIV-positive people taking Sustiva may be able to lower their levels of bad cholesterol by switching to Viramune (nevirapine).
June 08, 2007
People with HIV May Need Longer TB Treatment
(AIDSmeds.com) HIV-positive people with active TB are more likely to experience a relapse of the disease after receiving the same treatment typically used to treat HIV-negative TB patients.
June 07, 2007
Roche's Viracept Recalled; Pfizer's U.S. Version Okay
(AIDSmeds.com) Roche, the manufacturer of Viracept (nelfinavir) in all countries other than the U.S., Canada, and Japan, has recalled the drug. Pfizer's version used in the U.S. is okay.
June 06, 2007
New Drugs Possible from Discovered HIV Transport System
(AIDSmeds.com) Likening HIV to “hobos on a train,” researchers at Johns Hopkins University School of Medicine have found that the virus uses a pre-existing transport system to leave one infected CD4 cell and move on to infect news ones.
June 05, 2007
Early Treatment may have CD4 Advantage
(AIDSmeds.com) The chances of achieving and maintaining a CD4 count of 800 or higher are best among those who start antiretroviral therapy early, according to new data from the ATHENA cohort study.
Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
New HIV Vaccine Is Safe and Boosts Immune Reaction in Phase I Trial
Undetectable Viral Load? Not Necessarily in Semen
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
Misleading News Reports Suggest HIV Cure Is Near
Synthetic Compounds From Marijuana Appear to Fight HIV
14 French People With HIV Advance 'Functional Cure'
Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
 
Archive

June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
October 2005

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    charliehunter
    San Francisco
    California


    oceanblue65
    louisiana
    Louisiana


    hollywoodvers1
    Hollywood
    California


    jacob2608
    Panama City Beach
    Florida
Click here to join POZ Personals!
Conference Coverage

20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


XIX International AIDS Conference
(AIDS 2012)
Washington, DC
July 22 - 27, 2012


19th Conference on Retroviruses and Opportunistic Infections
(CROI 2012)
Seattle, Washington
March 5 - 8, 2012


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2013 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.